Status:

COMPLETED

A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer

Lead Sponsor:

The Christie NHS Foundation Trust

Collaborating Sponsors:

AstraZeneca

Conditions:

Non-Small Cell Lung Cancer

Eligibility:

All Genders

18+ years

Brief Summary

Participants with Non-Small Cell Lung Cancer (NSCLC), Performance Status (PS) 0-2, not suitable for concurrent Chemo-Radiotherapy (CTRT), will be treated with standard radiotherapy (radical or palliat...

Detailed Description

The purpose of this prospective, multicentre, non-randomised translational study is to provide proof of feasibility of achieving paired biopsies for PD-L1 assessment in patients with NSCLC treated wit...

Eligibility Criteria

Inclusion

  • Histologically confirmed NSCLC
  • Diagnostic/pre-treatment biopsy suitable for PD-L1 analysis\*
  • Tumour judged inoperable by a lung MDT
  • Tumour that is accessible to core biopsy
  • Age 18 and over, no upper age limit
  • Performance status (PS) - ECOG 0-2
  • Participant considered suitable for radiotherapy (palliative or radical) or sequential chemo-radiotherapy
  • Before participant registration, written informed consent must be given according to GCP and national regulations
  • Pre-treatment biopsy must be from gross tumour volume within planned radiation field, and must also:
  • have been formalin fixed for \>12h and ≤24h
  • have tumour tissue and morphology confirmed by H\&E staining
  • contain sufficient tumour cells (\>100) to determine PD-L1 status

Exclusion

  • Participant suitable for standard concurrent CTRT
  • Participant deemed unsuitable for repeat biopsies in the opinion of the treating oncologist
  • Participant known to have an EGFR mutation or an ALK rearrangement
  • Intercurrent or history of hepatitis B, C or human immunodeficiency virus infection, if known
  • Participants who have received more than 1 line of chemotherapy prior to radiotherapy

Key Trial Info

Start Date :

January 3 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 18 2020

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT03258788

Start Date

January 3 2019

End Date

March 18 2020

Last Update

April 3 2023

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

St. James's Univerisity Hospital

Leeds, United Kingdom, LS9 7TF

2

University College Hospital

London, United Kingdom, NW1 2BU

3

The Christie NHS Foundation Trust

Manchester, United Kingdom, M20 4BX